Monday, August 17, 2020

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

from Top Health News -- ScienceDaily https://ift.tt/317NlC5
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists say house cats could help unlock better cancer treatments for humans

Scientists have mapped the genetics of cat cancer on an unprecedented scale and found surprising similarities with tumors in humans. The fin...